The effect of casirivimab with imdevimab on disease progression in nonsevere COVID-19 patients in a single hospital in Japan.

Junpei KomagamineTaku YabukiSatsuki YoshiharaNao Tanaka

Published in: Journal of general and family medicine (2021)

Similar to other countries, casirivimab with imdevimab significantly reduced disease progression in early nonsevere COVID-19 patients with fever and risk factors in Japan.

Keyphrases

sars cov
risk factors
coronavirus disease
healthcare
respiratory syndrome coronavirus
acute care
emergency department
adverse drug